MAP3K14 and type 2 diabetes mellitus: This post hoc analysis of the EMBLEM trial on patients with T2D and established CVD, showed that the effects of 24 weeks of empagliflozin treatment on non-glycemic parameters, such as BMI and hs-TnI level, were more apparent in patients who had received baseline metformin therapy compared to metformin-naïve patients.